STEM:NASDAQ

StemCells Inc.

StemCells Inc. is engaged in the research and development of cell-based therapeutics. The company's proprietary HuCNS-SC cells (purified human neural stem cells) are currently in development as a potential treatment for a broad range of central nervous system disorders. The company is currently conducting phase 1/2 clinical trials in chronic spinal cord injury and dry age-related macular degeneration. StemCells Inc. is also pursuing preclinical studies in Alzheimer's disease, with support from the California Institute for Regenerative Medicine. The company markets stem cell research products, including media and reagents, under the SC Proven brand.

Expert Comments:

Jason Kolbert, Maxim Group (7/23/15)
"The U.S. District Court for the District of Maryland dismissed StemCells Inc.'s patent infringement case against Neuralstem Inc. with prejudice, in favor of Neuralstem. The case concerned certain patents surrounding StemCells's neuronal stem cells. . .we do not see this significantly impacting either company. We believe StemCells is continuing to make progress with the neuronal stem cell platform (dry-AMD and cervical spinal cord injury) and that progress should continue unimpeded by today's news. We continue to believe that with, with capital raised and multiple data-driving catalysts, 2015 is a year of inflection for StemCells."

Jason Kolbert, Maxim Group (7/20/15)
"StemCells Inc. continues to make progress with the neuronal stem cell platform. In addition to dry-AMD, the ongoing phase 2 'PATHWAY' study in cervical spinal cord injury could produce data later this year. We continue to believe that with capital raised and multiple data-drive catalysts that 2015 is a year of inflection for StemCells Inc."

Edward Woo, Ascendiant Capital Markets (6/30/15)
"The safety profile from StemCells Inc.'s Phase 1/2 study in dry age-related macular degeneration supports the recent initiation of the company's Radiant study, a Phase 2 controlled proof-of-concept trial. . .we expect 2015 to have significant clinical milestones for StemCells Inc. and additional data points to be released over the next year to be positive and a catalyst for the stock."

Jason Kolbert, Maxim Group (6/30/15)
"StemCells Inc. held a conference call yesterday to review previous data from the ongoing Phase 1/2 study in dry age-related macular degeneration. . .the totality of the data is actually quite good and suggestive of an efficacy signal with zero safety issues. . .we remain optimistic about the prospects for the current Phase 2 trial."

Ching-Yi Lin, H.C. Wainwright & Co. (6/30/15)
"Yesterday, StemCells Inc.'s management discussed topline results of its Phase 1/2 study in dry age-related macular degeneration. . .results from both cohorts showed safety and tolerability in addition to lower geographic atrophy growth rates in the study eye when compared to the fellow control eye. . .we believe there is demonstration of biological activity based on improvement seen in visual function and anatomical assessment."

Caroline Corner, Cantor Fitzgerald (6/29/15)
"This morning, StemCells Inc.'s management held a conference call to review the results of the Phase 1/2 dry age-related macular degeneration study. . .the trial demonstrated safety and the company is moving forward with the Radiant Phase 2 trial. We maintain our Buy rating and $2 price target."

More Expert Comments

Experts Commenting on This Company

Caroline Corner, Managing Director, Equity Research – Cantor Fitzgerald
Stephen Dunn, Senior Managing Director of Research – LifeTech Capital
Jolene Furdek, Senior Healthcare Analyst – Edison Investment Research
Katherine Genis, Analyst – Edison Investment Research
Christopher James, Managing Director, Senior Equity Research Analyst – FBR Capital Markets
Jason Kolbert, Senior Analyst – Maxim Group
Ching-Yi Lin, Managing Director in Equity Research, Senior Biotech Analyst – H.C. Wainwright & Co.
Henry McCusker, Founder and Director of Research – Scimitar Equity
Edward Woo – Ascendiant Capital Markets

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
StemCells Inc. Content